FDA U.S. FOOD & DRUG ADMINISTRATION
OFFICE OF REGULATORY AFFAIRS

July 28, 2017

Chelsea Church, PharmD, BCPS
Executive Director
Oklahoma State Board of Pharmacy
2920 Lincoln Blvd, Ste. A
Oklahoma City, Oklahoma 73105

Dear Ms. Church:

The purpose of this letter is to notify you that the U.S. Food and Drug Administration (FDA) does not intend to take further action with regard to an inspection of a pharmacy licensed by the Oklahoma Board of Pharmacy (BOP), Physician Preferred Medical, LLC dba PPM Pharmacy, located at 3300 NW 56th Street, Suite 101, Oklahoma City, OK 73112 (License #: 1-6190).

FDA inspected the firm from October 4, 2016, to October 11, 2016. The Oklahoma BOP was informed of the inspection but did not accompany FDA investigators during the inspection. No Form FDA 483 was issued to the firm.

During the inspection, the FDA investigators reviewed a small sample of records for products compounded by Physician Preferred Medical, LLC and determined, based on this sample, that this firm appears to obtain valid prescriptions for individually-identified patients for the drug products that it compounds and distributes.

FDA does not intend to take further action with regard to the findings of this inspection. Please notify us if you become aware of any adverse events or product quality concerns associated with drugs made at this facility, or if you observe any practices at this facility that concern you or that could be violations of Federal law.

We look forward to continuing to work with you on the oversight of compounding pharmacies. If you have additional questions, please contact me at 214-253-5288.

Sincerely,

John W. Diehl -S

Digitally signed by John W. Diehl -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=John W. Diehl -S, 0.9.2342.19200300.100.1.1=2000099727
Date: 2017.07.28 15:37:18 -05'00'

John W. Diehl
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations, Division II

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov